This is a topical and interesting area of study, as Th9 cells are a relatively a new subset, with many outstanding questions to be addressed. Here, Moretti et al. reported an interesting positive feedback loop amongst mast cells, ILC2 and Th9 cells to explain sustained IL-9 production in patients with cystic fibrosis. As presented, there are significant concerns with this paper, and some of the experiments are questionable and data may not their conclusions.
7. The authors state that MCs contribute to IL-2 production eventually leading to CD25+ ILC2 expansion . But the experiments presented by no means show that IL-2 is from MC, not from activated T cells during infection. Does exogenous IL-2 rescue CD25+ ILC2 expansion in Figure 4a (or Line 175-176)?
8. Although the authors found a significant association between T allele of IL9 gene and IgE production in females, the patient number is very small, and caution should be used in making definitive conclusions.
Reviewer #2 (Remarks to the Author):
Moretti et al describe a mast cell/ILC2/Th9 circuit that regulates inflammation during fungal infection in wild type and CFTR-mutant mice. The authors show increased IL-9, ILC2, mast cell, and Th9 expansion during A. fumigatus infection, and that these responses are exaggerated in the Cftr-/-mice. They show that IL-9/IL-9R is required for this response, and that IL-2 enhances Th9 cells cocultured with ILCs and indicated by expression of IL-9, IRF4 and PU.1. They show that IL-9 stimulates IL-2 production from mast cells, and that the response is significantly increased in the absence of Cftr. Mast cells are required for this circuit because Kit-Wsh mice and imatinib-treated mice have lower cytokine production and diminished Th9 gene expression. Finally the authors show sex specific effects of an IL9 polymorphism on IgE and IL-9 serum concentrations in CF patients. This is a novel and interesting report. The authors have used a variety of approaches for defining this cellular circuit in models of fungal infection in wild type and CFTR-mutant mice. The inclusion of correlations in data from patients adds to the depth of the study. However, there are conclusions made that are not entirely supported, and some assumptions made that are not necessarily valid. The following are needed to complete this story.
1. It is presumed that when the authors examine PU.1 and IRF4 expression they are performing these assays in purified CD4 T cells, as both of these genes can be expressed in many other cell types. It would be important to show that these cells are actually making or capable of making IL-9. Minimally this could be done with the mRNA samples to examine Il9 expression. Optimally, seeing CD4+ T cells that are IL-9+ by flow cytometry would be more convincing.
2. The authors show that mast cells when stimulated ex vivo can make IL-2 when stimulated with IL-9, but it is not clear this is occurring in vivo. The authors need to show flow cytometry of cells directly ex vivo (unstimulated or PMA/ionomycin) that are stained for IL-2 and then show how much of the IL-2 is coming from mast cells versus other cell types. They further need to show this is lacking in anti-IL-9 treated mice or Il9r-/-mice, and increased in the Cftr-mutant mice. Evidence for this link in the circuit is lacking.
3. In a similar point, the authors are not clearly showing the relative contribution of IL-9 from the various cell types. The authors seem to assume ILC2 cells are making IL-9 (Fig. 6 ), but this is never shown. Both CD4 T cells and mast cells are shown to make IL-9, but in separate assays where it's hard to compare production. At least at the level of mRNA (and optimally with flow cytometry) the authors need to provide a comparison of IL-9 production from the 3 cell types, probably at several time points, so a reader can appreciate, so a reader can appreciate what each is contributing to the environment.
4. One point that the authors never address either experimentally or in the discussion is where the CFTR is having an effect. Is it in the cells defined within this circuit or in the lung cells that lead to different responses from the cell types. Obviously this could be a whole new area, but I wonder if a reciprocal bone marrow chimera approach to recapitulate data in Fig. 1 would at least determine if CFTR was affecting this circuit from hematopoietic cells versus airway or other structural cell.
5. It is not clear that the authors have purified ILCs when they examine Rora. As this gene is expressed in many cell types, this is critical. In general, the figure legends need to be clearer on what cells are being examined in assays for gene expression and cytokine production.
6. In Fig. 4a , the authors need to show, at least by graph, a comparison of the numbers of mast cells and ILCs between the B6 and Kit-Wsh mice. As shown, the data in that panel is hard to interpret.
7. The title needs to be modified. The data from patient samples is strength, but it does not fully support the circuit, nor does it support a statement that this circuit impacts pathology. Similarly, the mouse model, while having the CF mutation, does not develop the same pathology as patients and the pathology being examined in this report is from acute fungal infection. The authors can decide how to handle this, but at least should include the phrase '....lung pathology in a mouse model of cystic fibrosis'.
8. The writing needs to be edited by a native English speaker; there were some parts that were hard to read and understand.
Reviewer #3 (Remarks to the Author):
The paper by Moretti shows novel data on the role of IL-9 in influencing ILC2 and mast cell accumulation in response to Aspergillosis exposure -the data of which appears to have relevance in fungal sensitization in CF. The paper is well written and the data are novel and largely support the conclusions. There are a few issue with controls that need to be clarified.
1.
In Figure 1 , the fungal burned needs to be shown as the increased pathology in the CFTR -/-mice could be due to greater antigen retention. Also total and fungal specific IgE responses, which is the hallmark of ABPA should be shown.
2.
It is unclear what the authors mean between infected vs ABAP in Figure 2b . This needs to be clarified. Again IgE levels should be shown here.
3
. Figure 3 should also include IgE. Can eth sash mice make IgE but not just activate mast cells?
4.
Did the authors assess Aspergillus specific IgE in the clinical cohort?
Reviewer #4 (Remarks to the Author):
"A mast cell/ILC2/Th9 pathway promotes lung pathology in cystic fibrosis" by Moretti and colleagues examines the contribution of several effector mechanisms typically studies in allergic airway disease in the setting of cystic fibrosis. The key approach here is the use of the cftr-/-mouse strain and studies on how these mice differ from controls in response to Aspergillus fumigatis infection. The authors reach the conclusion that there is a novel pathway through which mast cells coordinate with ILC2 cells to drive Th9 cell responses and pathogenesis. Importantly, the authors close the manuscript by showing associations of SNPs in the IL-9 locus with CF, which were rather intriguingly gender dependent.
In general, this study does provide aspects of data to support the fairly lengthy pathway that involves the three key cell types (mast cells, ILC2 and Th9) and the two key mediators (IL-2 and IL-9) but fail in the depth of inquiry to adequately determine if their conclusions are correct. The work also struggles in several places where there are points of the pathway that are not explained and/or the data seems to refute the mechanism to some degree. Consequently, the overall impression is that the work is an intriguing story but preliminary at this point.
Key specific areas of concern are as follows:
1)
A concern that has impact on much of the data shown relates to the basal phenotype differences between the WT and the cftr-/-strain. In several key figures, it is clear that there is a basal increase in many ILC2/Th2 cytokines and transcription factors (Fig 1C-F) and mast cells (Fig 3) that make it difficult to properly interpret the contribution of the cystic fibrosis phenotype versus the innate or adaptive response to Aspergillus. This point might be addressed using bone marrow chimerism approaches, which would allow for the epithelial dysfunction phenotype but a normal immune phenotype. At the least, this would help to define if the epithelial injury proposed in relation to Figure 3 is responsible for these basal enhancements in the model being used.
2)
This basal change has impact for several conclusions made, for example in L122 where the authors state that the Th9 response was sustained in the cftr-/-mice. Instead, it may simply be that the mice exhibited a more robust response than the WT and failed to resolve as quickly.
3)
The data in Figure 2h is concerning since it seems to counter the model being proposed, in which ILC2 activation supports the Th9 response. If this is so, the addition of IL-33 should surely have enhanced the IL-9 and transcription factor expression, which it does not seem to have done. Since IL-33 did not have any effects on the mast cell activation response shown in Figure 3 , it becomes a concern that 1) their IL-33 was not degraded or inactive, and 2) the dose investigated was insufficient.
4)
Assuming the model whereby IL-9 activates mast cells to produce IL-2, this alters the ILC2 and thereby drives Th9 is correct (as looks to be proposed), the key links between the ILC2 activation and Th9 responses remains unanswered.
5)
The authors frame the role of IL-33 in the context of epithelial damage leading to release but this thinking is a little out of date. McKenzies group demonstrated that the epithelial cells of the lung that are IL-33 expressing at the type 2 pneumocytes and not the bronchial epithelial cells that the authors show disruption of in Figure 3 .
6)
The use of the W-sh mice in this study do provide issues. In particular, as the authors seem to allude to in their supplementary figure, these mice exhibit a stronger neutrophilic response that would influence the fungal load. Ganeshan et al. have shown that mast cells regulate neutrophil apoptosis in the lungs and that these mice have increased neutrophilia because of alternations in local survival.
7)
The clinical data, while intriguing for the SNP, fails to convince for the IL-9 production in panel B. The variability would seem to suggest that more patients need to be done and that there are some high and low subgroups that might need to be considered. Also, some evidence that this SNP functionally alters transcription of the IL-9 gene would be useful, perhaps in the context of female hormones?
Minor issues: P5, L165 typo. Should read "not".
Point-by-point replay
Reviewer #1 (Remarks to the Author): This is a topical and interesting area of study, as Th9 cells are a relatively a new subset, with many outstanding questions to be addressed. Here, Moretti et al. reported an interesting positive feedback loop amongst mast cells, ILC2 and Th9 cells to explain sustained IL-9 production in patients with cystic fibrosis. As presented, there are significant concerns with this paper, and some of the experiments are questionable and data may not their conclusions.
Major concerns:
1. The authors stated that the late IL-9 production is T cell-dependent (Line 98-99), but experiments demonstrating this claim are incomplete. At the very least, FACS plots showing lung CD4 T cells or Lin-ILC2 that produce IL-9 are important, simply using non-Th9 specific transcriptional factors such as PU.1 and IRF4, or IL-9 production in a pool of lung cells are insufficient to define Th9 cells. Furthermore, mRNA assessment in a pool of lung cells does not truly define specific functions of a subset of Th cells.
Response. The reviewer may be right. However, Figure 1 shows that IL-9 production late in infection is ablated in Rag1
-/-mice. This observation along with that of Supplementary Fig. 1 
clearly shows that late IL-9 production is T cell-dependent. We have nevertheless incorporated in the new figure 1 FACS and immunofluorescence data showing the relative expression of IL-9 by ILC2 and CD4 + T cells in vivo and ex-vivo during infection. Moreover, we have made it clear in the respective figure legend that the transcription factor Rora (and now also Gata3) has been evaluated on lineage negative cells and Th9 transcripts, Pu.1 and Irf4, and now Il9, on purified CD4 + T cells.
2. The manuscript would be more informative if the authors could provide absolute numbers of Lung ILC2 cells (Figure 1b) , instead of only percentage, which can be misleading. The authors mentioned many times that CD25 + ILC2 expansion in Cftr -/-mice, but CD25 is expressed by many other cell types also. Figure 1c . 3. Upon Aspergillus fumigatus infection, the percentage of ILC2 is decreased dramatically (Fig 1b) , while the transcriptional factor RoRa, which is believed to ILC2, is increased in WT C57BL/6 mice (Fig 1c) . This paradox is not explained in the paper. Figure 1d ) that better correlates with the ILC2 dynamics. Figure 2C , the immune staining of the lung sections by CD90.2 and CD25 or ST2 is insufficient to define ILC2 cells. Activated T cells, even Tregs, are CD25 + , and should be stained also. However, IL9R KO lung sections are completely negative for CD25 staining, especially in mice infected with Aspergillus fumigatus where T cell activation is expected.
Response. We have provided the absolute number of lung ILC2 in

Response. The reviewer is correct. While the apparent increase in Rora mRNA expression is not statistically significant, we have added the Gata3 expression (new
In
Response. The reviewer is correct. Being IL-9R-deficient mice deficient of the IL-9Ra chain, they are also defective in CD25 expression. This minimizes the risk of assessing other CD25
+ cells. Figure 2h , several key controls are missing. The IL-2 and IL-33 only groups should be included to rule out any direct effect of IL-2 and IL-33 on CD4 T cells.
In
Response. The reviewer is right. However, the key controls were and still are in Supplemental Figure 4 . We have maintained these data in Supplemental Figure 4 for clarity.
6. In Figure 3e , in the ELISA assays performed for IL-9 production in cultures where exogenous IL-9 (100ng/ml) was added, how can you distinguish IL-9 produced from IL-9 added? 8. Although the authors found a significant association between T allele of IL9 gene and IgE production in females, the patient number is very small, and caution should be used in making definitive conclusions.
Response. We have increased the patient number as much as we could and the new data are now included. We would also share with this reviewer the concern about the small sample size of our cohort of patients. On acknowledging this limitation, a new sentence in the discussion has been added.
Reviewer #2 (Remarks to the Author):
Moretti et al describe a mast cell/ILC2/Th9 circuit that regulates inflammation during fungal infection in wild type and CFTR-mutant mice. The authors show increased IL-9, ILC2, mast cell, and Th9 expansion during A. fumigatus infection, and that these responses are exaggerated in the Cftr-/-mice. They show that IL-9/IL-9R is required for this response, and that IL-2 enhances Th9 cells co-cultured with ILCs and indicated by expression of IL-9, IRF4 and PU.1. They show that IL-9 stimulates IL-2 production from mast cells, and that the response is significantly increased in the absence of Cftr. Mast cells are required for this circuit because Kit-Wsh mice and imatinib-treated mice have lower cytokine production and diminished Th9 gene expression. Finally the authors show sex specific effects of an IL9 polymorphism on IgE and IL-9 serum concentrations in CF patients. This is a novel and interesting report. The authors have used a variety of approaches for defining this cellular circuit in models of fungal infection in wild type and CFTR-mutant mice. The inclusion of correlations in data from patients adds to the depth of the study. However, there are conclusions made that are not entirely supported, and some assumptions made that are not necessarily valid. The following are needed to complete this story.
1. It is presumed that when the authors examine PU.1 and IRF4 expression they are performing these assays in purified CD4 T cells, as both of these genes can be expressed in many other cell types. It would be important to show that these cells are actually making or capable of making IL-9. Minimally this could be done with the mRNA samples to examine Il9 expression. Optimally, seeing CD4 + T cells that are IL-9+ by flow cytometry would be more convincing.
Response. The reviewer is correct. We have incorporated in the new figure 1 FACS and immunofluorescence data showing the relative expression of IL-9 by ILC2 and CD4
+ T cells during infection. Moreover, the Il9 expression on purified CD4
+ T cells has been added.
2. The authors show that mast cells when stimulated ex vivo can make IL-2 when stimulated with IL-9, but it is not clear this is occurring in vivo. The authors need to show flow cytometry of cells directly ex vivo (unstimulated or PMA/ionomycin) that are stained for IL-2 and then show how much of the IL-2 is coming from mast cells versus other cell types. They further need to show this is lacking in anti-IL-9 treated mice or Il9r-/-mice, and increased in the Cftr-mutant mice. Evidence for this link in the circuit is lacking. 3. In a similar point, the authors are not clearly showing the relative contribution of IL-9 from the various cell types. The authors seem to assume ILC2 cells are making IL-9 (Fig. 6 ), but this is never shown. Both CD4 T cells and mast cells are shown to make IL-9, but in separate assays where it's hard to compare production. At least at the level of mRNA (and optimally with flow cytometry) the authors need to provide a comparison of IL-9 production from the 3 cell types, probably at several time points, so a reader can appreciate what each is contributing to the environment.
Response. Done. The new Figure 3 (panel f) incorporates now data on the comparative analysis of IL-
Response. Figure 1 now shows that ILC2 (panel b) and CD4 + T cells (panel h) are making IL-9, early and late in the infection, respectively. For IL-9 production by MC, the new Figure 3, panel b, shows that MC produce IL-9 (also mentioned in the text). Although in separate figures, we hope that these new data clearly provide the contribution of each cell type to IL-9 production.
4. One point that the authors never address either experimentally or in the discussion is where the CFTR is having an effect. Is it in the cells defined within this circuit or in the lung cells that lead to different responses from the cell types. Obviously, this could be a whole new area, but I wonder if a reciprocal bone marrow chimera approach to recapitulate data in Fig. 1 would at least determine if CFTR was affecting this circuit from hematopoietic cells versus airway or other structural cell.
Response. A totally new figure (Figure 5) and a new paragraph in the results is now devoted to the novel data obtained using bone marrow chimerism approaches.
Response. Rora has been examined in lung lineage negative cells and the figure legend has been modified accordingly.
Response. The graph has been added.
Response. We agree with the reviewer. However, to avoid excessive penalization of the human aspect of our study, we have taken the liberty to modify the title as follows: "A Mast Cells/ILC2/Th9 pathway promotes lung inflammation in Cystic Fibrosis". Should this new title not entirely fulfilling the reviewer's suggestion, we are happy to modify the title as suggested.
Response. Done.
Reviewer #3 (Remarks to the Author):
1. In Figure 1 , the fungal burden needs to be shown as the increased pathology in the CFTR-/-mice could be due to greater antigen retention. Also total and fungal specific IgE responses, which is the hallmark of ABPA should be shown.
Response. The suggestion is correct. We have already shown Figure 2b . This needs to be clarified. Again IgE levels should be shown here.
Response. We have specified in the text that mice were either acutely infected with Aspergillus conidia intranasally or subjected to ABPA by repeated sensitization with Aspergillus culture filtrate extracts, as described Reviewer #4 (Remarks to the Author):
"A mast cell/ILC2/Th9 pathway promotes lung pathology in cystic fibrosis" by Moretti and colleagues examines the contribution of several effector mechanisms typically studies in allergic airway disease in the setting of cystic fibrosis. The key approach here is the use of the cftr-/-mouse strain and studies on how these mice differ from controls in response to Aspergillus fumigatiu infection. The authors reach the conclusion that there is a novel pathway through which mast cells coordinate with ILC2 cells to drive Th9 cell responses and pathogenesis. Importantly, the authors close the manuscript by showing associations of SNPs in the IL-9 locus with CF, which were rather intriguingly gender dependent.
In general, this study does provide aspects of data to support the fairly lengthy pathway that involves the three key cell types (mast cells, ILC2 and Th9) and the two key mediators (IL-2 and IL-9) but fail in the depth of inquiry to adequately determine if their conclusions are correct. The work also struggles in several places where there are points of the pathway that are not explained and/or the data seems to refute the mechanism to some degree. Consequently, the overall impression is that the work is an intriguing story but preliminary at this point. Key specific areas of concern are as follows: 1) A concern that has impact on much of the data shown relates to the basal phenotype differences between the WT and the cftr-/-strain. In several key figures, it is clear that there is a basal increase in many ILC2/Th2 cytokines and transcription factors (Fig 1C-F) and mast cells (Fig 3) that make it difficult to properly interpret the contribution of the cystic fibrosis phenotype versus the innate or adaptive response to Aspergillus. This point might be addressed using bone marrow chimerism approaches, which would allow for the epithelial dysfunction phenotype but a normal immune phenotype. At the least, this would help to define if the epithelial injury proposed in relation to Figure 3 is responsible for these basal enhancements in the model being used. Figure 5 ) and a new paragraph in the results is now devoted to the novel data obtained using bone marrow chimerism approaches.
Response. A totally new figure (
2) This basal change has impact for several conclusions made, for example in L122 where the authors state that the Th9 response was sustained in the cftr-/-mice. Instead, it may simply be that the mice exhibited a more robust response than the WT and failed to resolve as quickly.
Response. The reviewer is right. Due to the epithelium and myeloid dysfunction, Cftr -/-mice have both a sustained Th9 response and a failure to resolve infection and inflammation.
3) The data in Figure 2h is concerning since it seems to counter the model being proposed, in which ILC2 activation supports the Th9 response. If this is so, the addition of IL-33 should surely have enhanced the IL-9 and transcription factor expression, which it does not seem to have done. Since IL-33 did not have any effects on the mast cell activation response shown in Figure 3 , it becomes a concern that 1) their IL-33 was not degraded or inactive, and 2) the dose investigated was insufficient.
Response. Figure 2h clearly 4) Assuming the model whereby IL-9 activates mast cells to produce IL-2, this alters the ILC2 and thereby drives Th9 is correct (as looks to be proposed), the key links between the ILC2 activation and Th9 responses remains unanswered.
Response. Correct. We agree with the reviewer that mechanisms linking ILC2 activation to Th9 responses are far from being known. Our intention was merely to assess whether ILC2 promoted Th9 cell activation via IL-9R signaling. In this regard, the data of Figure 2h and Supplementary Fig. 4 6) The use of the W-sh mice in this study do provide issues. In particular, as the authors seem to allude to in their supplementary figure, these mice exhibit a stronger neutrophilic response that would influence the fungal load. Ganeshan et al. have shown that mast cells regulate neutrophil apoptosis in the lungs and that these mice have increased neutrophilia because of alternations in local survival. 7) The clinical data, while intriguing for the SNP, fails to convince for the IL-9 production in panel B. The variability would seem to suggest that more patients need to be done and that there are some high and low subgroups that might need to be considered. Also, some evidence that this SNP functionally alters transcription of the IL-9 gene would be useful, perhaps in the context of female hormones?
Response. We have increased the patient number as much as we could and the new data are now included in the new Figure 5 ( 
